- Home
- RVPH vs RDI Comparison
RVPH vs RDI Comparison
Compare RVPH & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- RDI
- Stock Information
- Founded
- RVPH 2006
- RDI 1937
- Country
- RVPH United States
- RDI United States
- Employees
- RVPH N/A
- RDI N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- RDI Movies/Entertainment
- Sector
- RVPH Health Care
- RDI Consumer Discretionary
- Exchange
- RVPH Nasdaq
- RDI Nasdaq
- Market Cap
- RVPH 26.6M
- RDI 27.9M
- IPO Year
- RVPH N/A
- RDI N/A
- Fundamental
- Price
- RVPH $0.54
- RDI $1.40
- Analyst Decision
- RVPH Strong Buy
- RDI
- Analyst Count
- RVPH 5
- RDI 0
- Target Price
- RVPH $8.00
- RDI N/A
- AVG Volume (30 Days)
- RVPH 2.8M
- RDI 52.3K
- Earning Date
- RVPH 08-14-2025
- RDI 08-14-2025
- Dividend Yield
- RVPH N/A
- RDI N/A
- EPS Growth
- RVPH N/A
- RDI N/A
- EPS
- RVPH N/A
- RDI N/A
- Revenue
- RVPH N/A
- RDI $219,213,000.00
- Revenue This Year
- RVPH N/A
- RDI $7.47
- Revenue Next Year
- RVPH N/A
- RDI $13.22
- P/E Ratio
- RVPH N/A
- RDI N/A
- Revenue Growth
- RVPH N/A
- RDI 7.59
- 52 Week Low
- RVPH $0.30
- RDI $1.17
- 52 Week High
- RVPH $4.28
- RDI $1.89
- Technical
- Relative Strength Index (RSI)
- RVPH 61.01
- RDI 56.96
- Support Level
- RVPH $0.40
- RDI $1.33
- Resistance Level
- RVPH $0.48
- RDI $1.47
- Average True Range (ATR)
- RVPH 0.05
- RDI 0.06
- MACD
- RVPH 0.01
- RDI 0.01
- Stochastic Oscillator
- RVPH 58.53
- RDI 70.83
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.